Sleep Apnea ENT Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Obstructive sleep apnoea (OSA) is a highly prevalent sleep disorder characterised by repeated episodes of partial or complete upper airway collapse during sleep, causing apnoeas (cessation of airflow), hypopnoeas (reduced airflow), oxygen desaturation, and sleep fragmentation. OSA affects approximately 3–7% of adult men and 2–5% of adult women, with higher rates in obese individuals, increasing significantly to over 40% in those with BMI above 35. In children, adenotonsillar hypertrophy is the predominant anatomical cause, while in adults, multiple structural and neuromuscular factors at different pharyngeal levels contribute.

The gold standard diagnosis requires overnight polysomnography (PSG) — a comprehensive sleep study measuring airflow, respiratory effort, oxygen saturation, EEG, ECG, and limb movements — or alternatively, ambulatory limited-channel home sleep testing. The apnoea-hypopnoea index (AHI) quantifies severity: mild OSA (AHI 5–14), moderate OSA (AHI 15–29), and severe OSA (AHI greater than 30). Untreated OSA is associated with hypertension, cardiovascular disease, type 2 diabetes, depression, cognitive impairment, and significantly increased road traffic accident risk from daytime sleepiness.

First-line management of adult OSA is continuous positive airway pressure (CPAP) therapy, which pneumatically splints the upper airway during sleep. However, long-term CPAP adherence is a major challenge, with approximately 30–50% of prescribed patients using CPAP less than four hours per night — the minimum accepted therapeutic threshold. ENT surgical interventions offer targeted anatomical correction for patients who are intolerant of or non-adherent to CPAP and have specific surgically addressable upper airway obstruction sites identified on clinical assessment, endoscopy, and drug-induced sleep endoscopy (DISE).

ENT surgical approaches for OSA address specific anatomical levels of upper airway obstruction. Nasal obstruction contributing to OSA through increased nasal resistance, forced mouth breathing, and impaired CPAP tolerance is addressed by septoplasty for deviated septum and turbinate reduction for turbinate hypertrophy. While nasal surgery alone rarely cures OSA, it significantly improves CPAP adherence (reducing required pressure by 1–4 cmH2O) and is an important adjunct to other interventions.

Palatopharyngeal obstruction from tonsillar hypertrophy and excessive soft palate or uvula tissue is addressed by tonsillectomy, uvulopalatopharyngoplasty (UPPP), and palatal expansion procedures. UPPP — which removes the uvula, excess soft palate mucosa, and tonsils — targets retropalatal collapse and achieves success (AHI reduction greater than 50% and to below 20) in approximately 40–50% of appropriately selected cases. Tongue base obstruction — identified on DISE as the collapse point in many CPAP-intolerant patients — is addressed by radiofrequency tongue base reduction, lingual tonsillectomy, or hypoglossal nerve stimulation (HNS). In children, adenotonsillectomy (combined adenoid and tonsil removal) is the primary surgical treatment for OSA caused by adenotonsillar hypertrophy, achieving resolution in 70–80% of otherwise healthy children and warranting consideration before any CPAP trial.

ENT surgical candidacy for OSA requires: a confirmed OSA diagnosis on polysomnography or equivalent, failure or intolerance of at least three months of CPAP therapy, specific identifiable surgically addressable anatomy, and absence of contraindications to general anaesthesia. Drug-induced sleep endoscopy (DISE) — a validated assessment performed under conscious sedation in which a flexible nasopharyngoscope evaluates the dynamic airway during simulated sleep — guides surgical site selection and is increasingly considered mandatory before undertaking pharyngeal or tongue base surgery for OSA.

Hypoglossal nerve stimulation (Inspire HNS) has specific candidacy criteria: AHI 15–65, BMI below 32 (in the original pivotal trial criteria, though some programmes accept up to 35), absence of complete concentric palatal collapse on DISE (which predicts poor response), and non-positional OSA. Paediatric OSA candidacy for adenotonsillectomy is established by clinical findings and polysomnography when available; tonsillar hypertrophy grading and clinical symptoms of nocturnal breathing difficulty guide decision-making in practice. Contraindications to UPPP include predominantly retroglosssal or tongue base collapse without palatal component, absence of tonsillar tissue (for which the expected benefit is reduced), and morbid obesity (BMI above 40) where weight loss and CPAP are preferable first-line interventions.

Tonsillectomy and adenotonsillectomy for paediatric OSA is performed under general anaesthesia using cold steel (traditional), electrocautery, coblation, or laser techniques. Coblation tonsillectomy uses radiofrequency plasma energy to dissolve tonsillar tissue at low temperature, with evidence for less postoperative pain and faster return to normal diet compared to electrocautery. The procedure takes 20–30 minutes and is performed as a day case in most centres.

Uvulopalatopharyngoplasty (UPPP) removes excess soft palatal, uvular, and pharyngeal tissue to widen the retropalatal airway. Variations include anterior palatoplasty, lateral pharyngoplasty (Z-pharyngoplasty, expansion sphincter pharyngoplasty), and barbed reposition pharyngoplasty — techniques that reposition rather than resect tissue, aiming to reduce velopharyngeal insufficiency risk and improve long-term outcomes compared to classical UPPP. Multi-level surgery combining palatal surgery with nasal and tongue base procedures may be performed in selected patients.

Hypoglossal nerve stimulation (Inspire Therapy, ResMed Genio) is a fully implantable device that detects respiratory effort and delivers mild electrical stimulation to the hypoglossal nerve (nerve XII) on each inhalation, causing the genioglossal tongue muscle to protract forward, opening the retroglossal and retropalatal airway. Implantation is performed under general anaesthesia with a two to three-hour procedure; activation occurs one month post-implantation with stimulation amplitude titrated during an attended overnight titration polysomnography. Mandibular advancement devices (MAD) are custom-fitted oral appliances that advance the mandible and tongue base forward during sleep, providing a non-surgical alternative with evidence comparable to UPPP in mild-to-moderate OSA.

Adenotonsillectomy for paediatric OSA achieves polysomnographic resolution (AHI below 1 per hour) in approximately 70–80% of otherwise healthy children and significant improvement in a further 10–15%, with accompanying improvements in behaviour, school performance, quality of life, and reduction in bedwetting. Long-term cardiovascular and metabolic benefits of early OSA treatment in children are increasingly well-documented.

The STAR trial of hypoglossal nerve stimulation (Inspire) demonstrated 68% of patients achieving surgical success (AHI reduction greater than 50% to below 20) at 12 months, with 86% response maintained at 5 years. The Oxygen Desaturation Index (ODI) improved by 70%, Epworth Sleepiness Score improved by 3–4 points, and patient-reported outcomes were significantly better than sham controls. UPPP with modern lateral pharyngoplasty techniques achieves surgical success rates of 60–70% in carefully selected patients with predominantly retropalatal collapse identified on DISE. Nasal surgery significantly improves CPAP adherence (by 30–40% in RCTs) in patients whose primary barrier to CPAP use is nasal obstruction.

UPPP carries specific risks including postoperative nasopharyngeal oedema requiring airway monitoring overnight in moderate-to-severe OSA, post-tonsillectomy haemorrhage (2–5%, with secondary bleeding at five to ten days requiring emergency attendance), velopharyngeal insufficiency causing nasal regurgitation (1–3% with modern techniques), change in voice quality, dry throat, and recurrence of OSA with weight gain over time. Post-UPPP patients also lose the ability to use CPAP effectively through some mask types due to palatal changes, making careful preoperative selection crucial.

Hypoglossal nerve stimulation implantation risks include surgical site infection (2%), stimulation site pain (6%), temporary tongue weakness (3%), and device-related complications requiring revision (3% over 5 years). Electrical stimulation discomfort is the most common reason for parameter adjustment in the first months after activation. MRI access is restricted to 1.5 Tesla MRI with specific protocols for patients with Inspire devices. Paediatric tonsillectomy risks include secondary haemorrhage (2–4%), pain management difficulties, and rarely post-obstructive pulmonary oedema in severe pre-operative OSA patients managed in overnight monitored settings.

Post-tonsillectomy or UPPP patients are monitored overnight if moderate-to-severe OSA is present, as immediate post-operative airway swelling can paradoxically worsen obstruction transiently. Discharge the following day with regular liquid analgesia, soft diet for ten to fourteen days, and clear bleeding precaution instructions is standard. Activity restriction for two weeks reduces secondary haemorrhage risk. ENT review at two to four weeks assesses healing.

For HNS (Inspire), activation occurs at one month post-implantation. An attended titration polysomnography at one to two months after activation optimises stimulation parameters. Remote app-based adjustment and annual attended polysomnographic review are standard follow-up. The device requires battery replacement approximately every eleven years with a brief replacement procedure. All surgically treated OSA patients should undergo repeat PSG at three to six months post-procedure to document objective AHI response, guide ongoing CPAP decisions, and identify residual OSA requiring additional treatment. OSA treatment is chronic disease management — weight control, ongoing monitoring, and readiness to add CPAP for residual disease are essential elements of long-term care.

Adenotonsillectomy for paediatric OSA in the US costs $4,000–$9,000 as a day procedure; insurance coverage is standard when medical necessity is documented. UPPP in the US costs $7,000–$15,000 and is covered by most insurers for OSA failing CPAP. Hypoglossal nerve stimulation (Inspire) costs $25,000–$40,000 including device, surgery, and activation in the US; FDA approval since 2014 means insurance coverage is increasingly available with documentation of CPAP failure. In the UK, both UPPP and HNS are available on the NHS through specialist sleep and ENT services, with waiting times of 12–24 months.

International medical tourism for OSA surgery offers significant savings. Adenotonsillectomy in India costs $800–$2,000; UPPP at accredited ENT centres in India, Thailand, and Malaysia costs $3,000–$7,000 compared to $15,000+ in the US. Hypoglossal nerve stimulation implantation is available at selected centres in India and Southeast Asia at 40–60% lower cost than US prices, though device availability may vary. Patients pursuing international OSA surgery should ensure access to post-operative polysomnography for objective outcome assessment.

Continuous positive airway pressure (CPAP) remains the gold standard first-line treatment for adult moderate-to-severe OSA, with the highest efficacy of any OSA intervention when used consistently (at least four hours per night). Modern CPAP devices with heated humidification, auto-titration (APAP), and data-tracking via smartphone app have significantly improved adherence. Mandibular advancement devices (MAD), custom-fitted by a dental sleep medicine practitioner, are a non-surgical alternative for mild-to-moderate OSA and CPAP-intolerant patients, with meta-analyses showing AHI reduction of 50–60% — less than CPAP but with better adherence in selected patients.

Weight loss intervention (supervised low-calorie diet, GLP-1 receptor agonists, or bariatric surgery) is a critical adjunct treatment for overweight and obese OSA patients, as each 10% weight reduction reduces AHI by approximately 26% in cohort studies. Positional therapy (avoidance of supine sleeping, positional alarm devices) benefits patients with predominantly positional OSA (AHI two to three times worse supine than lateral). Myofunctional therapy — structured oropharyngeal exercises strengthening the tongue and pharyngeal muscles — shows significant AHI reduction in RCTs (average 50% AHI reduction, 36% reduction in Epworth score) and is recommended as an adjunct to other treatments. Nasal EPAP devices and oral pressure devices represent further non-surgical alternatives.